Surgical Management of Non-small Cell Lung Cancer With Synchronous Brain Metastases

Bonnette, P.; Puyo, Philippe; Gabriel, C. Levy; Giudicelli, R; Régnard, Jean-François; Riquet, Marc; Brichon, Pierre-Yves

doi:10.1378/chest.119.5.1469

Cited by 171 publications

(141 citation statements)

References 19 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…13,14 Similarly, some studies found no survival difference according to nodal status, 5,20 whereas other studies demonstrate longer survival in lymph node negative patients compared with lymph node positive patients. 9,10 In this study age was also significant for survival in patients undergoing treatment of their brain metastases. On the basis of our results, we recommend that selected patients less than 65-years-old with stage I/II thoracic disease, who are eligible to undergo aggressive cranial treatment, should also be considered for radical thoracic treatment.…”

Section: Discussionmentioning

confidence: 58%

“…Other authors have reported similar findings in selected patients, with OS ranging from 12.4 to 24 months, 1-year survival rates from 35% to 80%, and 5-year survivals from 25% to 70%. 4,9,10,14,[18][19][20] (Most studies reported that the prognosis of patients undergoing surgical resection for a synchronous BM from NSCLC mainly depended on the treatment of the lung tumor, with a survival advantage seen in patients receiving radical treatment (surgery or radiotherapy). 12,14,21 After SRS for solitary synchronous BM from NSCLC, a significantly longer OS (26.4 months) was similarly seen in patients who underwent radical thoracic treatment (surgery or chemoradiotherapy) than those undergoing palliative treatment (13.1 months).…”

Section: Discussionmentioning

confidence: 99%

“…Some reports suggest that survival in such patients is influenced by the treatment modality used for an intrathoracic tumor, with radical treatment strategies (surgery or high-dose thoracic radiotherapy) effecting extended survival. [9][10][11][12][13][14][15] However, such data are mainly limited to retrospective analyses of small numbers of patients with a single brain metastasis and no extracranial metastases (oligometastatic disease). As the majority of patients with NSCLC present with multiple brain metastases and/or extensive extracranial disease, they are ineligible for such treatment.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Time for reappraisal of extracranial treatment options?

Lind

Lagerwaard

Smit

et al. 2010

Cancer

View full text Add to dashboard Cite

Cyclodextrins (CD) are produced from starch by the action of cyclodextrin glycosyltransferase (CGTase) enzyme. Structurally, cyclodextrins consist of 6, 7, or 8 (α, β, and γ cyclodextrins, respectively) D‐glucopyranosyl units connected by α‐(1,4) glycosidic linkages. Having polar and hydrophilic outer sides and hydrophobic cavitation gives cyclodextrins a chance to form inclusion complexes with dyes in hydrophilic mediums. In this research, the equalizing effect of β‐cyclodextrins in dyeing of polyamide 6,6 woven fabrics with 6 different acid dyes were investigated. From the experimental results, it was determined that the β‐cyclodextrin shows a retarding and equalizing effect in dyeings carried out with the dyes that show interaction with β‐CD. © 2006 Wiley Periodicals, Inc. J Appl Polym Sci 103: 2660–2668, 2007

show abstract

Section: Discussionmentioning

confidence: 58%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Time for reappraisal of extracranial treatment options?

Lind

Lagerwaard

Smit

et al. 2010

Cancer

View full text Add to dashboard Cite

show abstract

“…These patients may benefit from surgical resection of the primary tumor and its metastasis. Several retrospective case studies have documented an improved outcome in patients treated surgically, but most studies reported only on isolated metastasis of the brain or adrenal gland [7][8][9][10]. Therefore, it is unknown whether patients with an isolated metastasis in other locations also benefit from this aggressive approach.…”

Section: Introductionmentioning

confidence: 99%

“…Therefore, it is unknown whether patients with an isolated metastasis in other locations also benefit from this aggressive approach. Recently, Salah et al reviewed 51 cases to analyze the outcome of extrapulmonary, extracerebral, and extraadrenal oligometastatic NSCLC [7][8][9][10][11]. The 5-year overall survival rate was 50 %, which implies a high publication bias.…”

Section: Introductionmentioning

confidence: 99%

Surgical Treatment of Extrapulmonary Oligometastatic Non-small Cell Lung Cancer

et al. 2012

View full text Add to dashboard Cite

The prognosis of metastatic non-small cell lung cancer (NSCLC) is poor, and platinum-based chemotherapy improves the median survival for only a few months. A subgroup of patients with oligometastatic disease may benefit from surgical resection, but only very limited data are available to date. We conducted a retrospective review of all patients with synchronous extrapulmonary oligometastatic NSCLC undergoing surgical resection in our department. Data regarding medical history, histology, number of metastases, and survival status were extracted from the medical database

show abstract

Survival benefits of primary tumor surgery for synchronous brain metastases: A SEER‐based population study with propensity‐matched comparative analysis

Zhang

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Background Evidence about the prognostic value of primary tumor surgery (PTS) in patients with brain metastatic malignancies is ambiguous and controversial. This study assessed the survival benefits of primary tumor surgery in patients with brain metastases (BMs). Methods Adults patients with BMs that originated from lung, breast, kidney, skin, colon, and liver diagnosed between 2010 and 2018 were derived from the Surveillance, Epidemiology, and End Results database (SEER). Propensity score matching (PSM) was used to balance the bias between patients with or without PTS. Then the prognostic value of PTS was estimated by Kaplan–Meier analysis and Cox proportional hazard regression models. Results A total of 32,760 patients with BMs secondary to non‐small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer, renal cancer, melanoma, colorectal cancer, and liver cancer were identified from the database. After PSM at 1:1 ratio, PTS appeared to significantly prolong cause‐specific survival (CSS) time for patients with BMs secondary to NSCLC, breast cancer, renal cancer, and colorectal cancer (hazard ratio [HR] = 0.60 [0.53–0.68], 0.56 [0.43–0.73], 0.47 [0.37–0.60], and 0.59 [0.37–0.95], respectively, all p < 0.05). Patients with earlier T and N classifications, no extracranial metastasis, and cancer‐specific subtypes (adenocarcinoma in NSCLC, hormone receptor‐negative breast cancer) may derive more survival benefits from PTS when suffering from BMs. Conclusion This population‐based study supported PTS could provide survival benefits for patients with BMs secondary to NSCLC, breast cancer, renal cancer, and colorectal cancer. More emphasis should be put on PTS of selected patients with BMs.

show abstract

Surgical Management of Non-small Cell Lung Cancer With Synchronous Brain Metastases

Cited by 171 publications

References 19 publications

Time for reappraisal of extracranial treatment options?

Time for reappraisal of extracranial treatment options?

Surgical Treatment of Extrapulmonary Oligometastatic Non-small Cell Lung Cancer

Survival benefits of primary tumor surgery for synchronous brain metastases: A SEER‐based population study with propensity‐matched comparative analysis

Contact Info

Product

Resources

About